"10.1371_journal.pctr.0010034","plos clinical trials","2006-11-24T00:00:00Z","Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Dapa A Diallo; Issaka Sagara; Alassane Dicko; David J Diemert; D Gray Heppner; V Ann Stewart; Evelina Angov; Lorraine Soisson; Amanda Leach; Kathryn Tucker; Kirsten E Lyke; Christopher V Plowe; for the Mali FMP1 Working Group","Malaria Research and Training Center, University of Bamako, Bamako, Mali; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America; Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America; United States Agency for International Development, Washington, D. C., United States of America; GlaxoSmithKline Biologicals, Rixensart, Belgium; Statistics Collaborative, Washington, D. C., United States of America; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America","MAT, OKD, DAD, IS, AD, DJD, DGH, LS, AL, and CVP designed the study. MAT, AD, OKD, DAD, IS, DJD, DGH, EA, LS, KT, and CVP analyzed the data. MAT, OKD, DC, DAD, AD, and CVP enrolled patients. MAT, OKD, DC, DAD, AD, DJD, DGH, VAS, EA, LS, AL, KT, KEL, and CVP wrote the paper.","EA holds patents for production of the FMP1 antigen and, together with Joe Cohen, has filed a patent application for the formulation of FMP1 with the proprietary AS02A adjuvant. AL, W. Ripley Ballou, and Joe Cohen are employees of GlaxoSmithKline Biologicals, the manufacturer of the proprietary adjuvant AS02A, and hold shares in GlaxoSmithKline. DGH has applied for a patent with coauthors from GlaxoSmithKline for a malaria vaccine not described in this paper. GlaxoSmithKline is a major partner in the Department of Defense Malaria Vaccine Program.","2006","11","Mahamadou A Thera","MAT",16,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
